| Literature DB >> 29312902 |
Marie-Luise Decker1, Martin P Grobusch2,3, Nicole Ritz1,4.
Abstract
Cytokines have attracted much attention as diagnostic biomarkers for infectious and inflammatory diseases in recent years. However, understanding of maturation and normal age-associated values is limited. This review summarizes evidence on the influence of age and other factors on expression profiles of soluble and intracellular cytokines in healthy children. IFN-γ, IL-6, IL-10, and TNF-α are the most frequently investigated cytokines, of which an age-associated increase was shown consistently for IFN-γ and TNF-α. An age-associated decrease of IL-13 was seen in resource-limited settings. For other cytokines, including IL-1RA, IL-2, and IL-10, uni- or bimodal curves have been described, and results were influenced by study setting. To conclude, despite limited current understanding of the development of cytokine expression, age clearly influences expression profiles in healthy children. Dynamics of cytokine expression in childhood need to be considered when these are measured in diagnostic assays or as biomarkers. In addition, cytokine-targeting agents may require adjustment for normal values when used in children.Entities:
Keywords: adolescent; age influence; children; cytokine expression; gender; infant; sex
Year: 2017 PMID: 29312902 PMCID: PMC5735141 DOI: 10.3389/fped.2017.00255
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.418
Figure 1Flow diagram of selected articles included in the review.
Studies included in final analysis with baseline characteristics, cytokines analyzed and method chosen for analysis.
| Reference | Year | Country | Child age range (years) | % Female (child) | GM-CSF | IFN-γ | IL-1β | IL-1ra | IL-2 | IL-4 | IL-5 | IL-6 | IL-7 | IL-8 | IL-10 | IL-12 | IL-13 | IL-23 | IP-10 | MCP-1 | MIP-1 α | MIP-1β | TNF-α | Other | SCA | ICA | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sack et al. ( | 1997 | DE | – | 275 | – | 3–17 | – | ● | ● | ● | ● | ● | ● | ||||||||||||||||
| Chipeta et al. ( | 1998 | JP | 19 | 16 | 12 | 0–14 | – | ● | ● | ● | ● | ||||||||||||||||||
| Smart and Kemp ( | 2001 | AU | – | 50 | – | 0–16 | – | ● | ● | ● | ● | ● | |||||||||||||||||
| Upham et al. ( | 2002 | AU | 30 | 84 | 12 | 0–12 | – | ● | ● | ● | |||||||||||||||||||
| Gasparoni et al. ( | 2003 | IT | 44 | 10 | 10 | 0–10 | – | ● | ● | ● | ● | ● | |||||||||||||||||
| Berdat et al. ( | 2003 | CH | – | 79 | – | 0.2–4.5 | – | ● | ● | ● | ● | ||||||||||||||||||
| Timmons et al. ( | 2005 | CA | – | 58 | – | 12–14 | 43 | ● | ● | ● | ● | ||||||||||||||||||
| Härtel et al. ( | 2005 | DE | 18 | 54 | 19 | 0–8 | – | ● | ● | ● | ● | ● | ● | ● | ● | ● | |||||||||||||
| Hoffmann et al. ( | 2005 | DE | – | 46 | 33 | 0–17 | – | ● | ● | ● | ● | ● | ● | ||||||||||||||||
| Okamoto et al. ( | 2005 | JP | – | 55 | 44 | 1–14 | 35 | TGF-β1 | ● | ||||||||||||||||||||
| Vaisman et al. ( | 2006 | IL | – | 21 | – | 8–12 | 36 | ● | ● | ● | ● | ● | ● | ||||||||||||||||
| Yerkovich et al. ( | 2007 | AU | 10 | 27 | 10 | 0–13 | – | ● | ● | ● | ● | ● | ● | ● | ● | ||||||||||||||
| Eriksson et al. ( | 2007 | GW | – | 50 | 11 | 0.4–0.5 | 44 | ● | ● | ● | ● | ● | |||||||||||||||||
| Wiegering et al. ( | 2009 | DE | 25 | 92 | – | 0–18 | 42 | ● | ● | ● | ● | ● | |||||||||||||||||
| Figueiredo et al. ( | 2009 | BR | – | 1356 | – | 4–11 | 46 | ● | ● | ● | ● | ● | |||||||||||||||||
| Raes et al. ( | 2010 | BE | – | 202 | – | 0.2–0.5 | 43 | ● | ● | ● | ● | ● | ● | ● | |||||||||||||||
| Nguyen et al. ( | 2010 | BE | 13 | 30 | 30 | 0–1 | 60 | ● | ● | ● | ● | ● | ● | ● | MIG | ● | |||||||||||||
| Teran et al. ( | 2011 | EC | – | 240 | – | 0.5–5 | 52 | ● | ● | ● | ● | ● | ● | ● | ● | ||||||||||||||
| Burl et al. ( | 2011 | GM | 15 | 105 | – | 0–1 | – | ● | ● | ● | ● | ● | ● | ||||||||||||||||
| Lisciandro et al. ( | 2012 | PG | – | 67 | – | 0.1–1.5 | – | ● | ● | ● | ● | ● | ● | ||||||||||||||||
| Reikie et al. ( | 2012 | SA | – | 28 | 10 | 0–1 | – | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | IFN-α | ● | |||||||||
| Kleiner et al. ( | 2013 | IT | – | 37 | 35 | 1–17 | 59 | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ||
| Djuardi et al. ( | 2016 | ID | – | 119 | 119 | 0.2–2 | – | ● | ● | ● | ● | ● | ● | ||||||||||||||||
| Dorn et al. ( | 2016 | US | – | 262 | – | 11–17 | 100 | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | |||||||
| Total | 174 | 3244 | 226 | 2 | 19 | 6 | 3 | 8 | 9 | 8 | 12 | 2 | 8 | 18 | 7 | 6 | 3 | 4 | 2 | 2 | 2 | 18 | 20 | 6 |
SCA, soluble cytokine assays (i.e., in serum or supernatants); ICA, intracellular cytokine assay measured using flow cytometry.
.
.
.
Proportions of cytokine-producing cells in stimulated CD4 T cells from healthy neonates and children (flow-cytometry data).
| Age (years) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reference | Cord blood preterm | Cord blood term | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | Adults |
| Chipeta et al. ( | 0.2 | 3.8 | 7.3 | ||||||||||||||||||
| Gasparoni et al. ( | 1.0–1.6 | 0.8 | 4.7 | 10.9 | |||||||||||||||||
| Hoffmann et al. ( | 3.7 | 13.9 | 11.6 | 18.7 | 21.6–23.2 | ||||||||||||||||
| Wiegering et al. ( | 4.0 | 8.0 | 11.0 | 13 | 17 | ||||||||||||||||
| Chipeta et al. ( | 56.4 | 41.2 | 42.4 | ||||||||||||||||||
| Gasparoni et al. ( | 61.2–54.0 | 51.3 | 21.3 | 31.5 | |||||||||||||||||
| Hoffmann et al. ( | 4.9 | 9.7 | 8.6 | 13.2 | 12.4–62.8 | ||||||||||||||||
| Wiegering et al. ( | 71 | 14 | 29 | 26 | 37 | ||||||||||||||||
| Gasparoni et al. ( | 0.4–0.6 | 0.4 | 1.3 | 1.6–4.2 | |||||||||||||||||
| Hoffmann et al. ( | 0.5 | 1.4 | 1.5 | 1.7 | 21.6–23.2 | ||||||||||||||||
| Wiegering et al. ( | 0.6 | 1.0 | 1.0 | 1.0 | 1.0 | ||||||||||||||||
| Gasparoni et al. ( | 0.9 | 0.4 | – | 10.9 | |||||||||||||||||
| Hoffmann et al. ( | 0.2 | 0.5 | 1.1 | 1.1 | 1.3–1.7 | ||||||||||||||||
| Hoffmann et al. ( | 3.7 | 13.9 | 11.6 | 18.7 | 21.6–23.2 | ||||||||||||||||
| Wiegering et al. ( | 4.0 | 17.0 | 22.0 | 24.0 | 25.0 | ||||||||||||||||
Proportions of cytokine-producing cells in stimulated CD8 T cells from healthy neonates and children (flow cytometry data).
| Age (years) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reference | Cord blood preterm | Cord blood term | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | Adults |
| Chipeta et al. ( | 2.8 | 16.6 | 36.1 | ||||||||||||||||||
| Gasparoni et al. ( | 3.6–4.6 | 4.6 | 20.0 | 27.7 | |||||||||||||||||
| Hoffmann et al. ( | 10.6 | 30.3 | 28.1 | 34.6 | 38.9–55.8 | ||||||||||||||||
| Wiegering et al. ( | 9.0 | 21.0 | 13.0 | 15.0 | 22.0 | ||||||||||||||||
| Chipeta et al. ( | 18.7 | 14.3 | 8.5 | ||||||||||||||||||
| Gasparoni et al. ( | 18.9–37.0 | 23.2 | 12.1 | 13.9 | |||||||||||||||||
| Hoffmann et al. ( | 1.2 | 0.3 | 1.3 | 0.4 | 1.8–4.8 | ||||||||||||||||
| Wiegering et al. ( | 50.0 | 18.0 | 18.0 | 18.0 | 25.0 | ||||||||||||||||
| Gasparoni et al. ( | 1.4 | 1.7 | 0.7 | 0.5 | |||||||||||||||||
| Hoffmann et al. ( | 0.1 | 0.1 | 0.7 | 0.1 | 0.2–1.4 | ||||||||||||||||
| Wiegering et al. ( | 1.0 | 1.0 | 2.0 | 1.0 | 1.0 | ||||||||||||||||
| Gasparoni et al. ( | 1.1–2.0 | 2.2 | – | – | |||||||||||||||||
| Hoffmann et al. ( | 0.04 | 0.04 | 0.04 | 0.04 | 0.1–0.2 | ||||||||||||||||
| Hoffmann et al. ( | 4.7 | 12.9 | 10.3 | 17.0 | 18.1–56.5 | ||||||||||||||||
| Wiegering et al. ( | 7.0 | 21.0 | 20.0 | 26.0 | 23.0 | ||||||||||||||||
Age correlation of cytokine expression in flowcytometry studies.
| Chipeta et al. ( | Gasparoni et al. ( | Härtel et al. ( | Hoffmann et al. ( | Yerkovic et al. ( | Wiegering et al. ( | Reikie et al. ( | |
|---|---|---|---|---|---|---|---|
| Sample type | CBMC and PBMC | Frozen CBMC and PBMC | Whole blood from cord and venous samples | Whole blood | Frozen CBMC and PBMC | Whole blood from cord and venous samples | Whole blood |
| Stimulant | PMA/ionomycin | PMA/ionomycin | LPS PMA/ionomycin | PMA/ionomycin | LPS | PMA/ionomycin | TLR-agonist 1–4, 7–8, NOD-receptor agonist 1/2 |
| Duration of stimulation (h) | 12 | 4 | 5 (IFN-γ, IL-12, TNF-α) | 6 | 24 | 24 | 6 |
| INF-γ | CD4 | CD4 | CD3 | CD4 | CD4 | – | |
| CD8 | CD8 | CD8 | CD8 | ||||
| IL-2 | CD4 | CD4 | – | CD4 | CD4 | – | |
| CD8 | CD8 | CD8 | CD8 | ||||
| IL-4 | ULQ | CD4 | – | CD4 | CD4 | – | |
| CD8 | CD8 | CD8 | |||||
| IL-6 | CD 14 (monocytes) | Monocytes | |||||
| Dendritic cells | |||||||
| IL-10 | – | CD4 | – | CD4 | – | – | |
| CD8 | CD8 | ||||||
| IL-12 | – | – | CD14 | – | – | – | |
| TNF-α | – | – | CD3 | CD4 | CD14 (monocytes) | CD4 | Monocytes |
| CD8 | CD8 | Dendritic cells | |||||
Negative age correlations are shown in red, positive age correlations in green, and absence of age correlations in gray. Only parameters investigated in more than one study are listed.
–, not analyzed; CBMC, cord blood mononuclear cell; PBMC, peripheral blood mononuclear cell, LPS, lipopolysaccharide, PMA, phorbol myristate acetate, ULQ, under the lower limit of quantification.
.
.
Summary of results in studies reporting age association of secreted cytokines using stimulated samples.
| Reference | Smart and Kemp ( | Upham et al. ( | Härtel et al. ( | Yerkovich et al. ( | Errikson et al. ( | Figueiredo et al. ( | Nguyen et al. ( | Teran et al. ( | Burl et al. ( | Lisciandro ( | Reikie ( | Djuardi ( |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (years) | 0–16 | 0–12, Adult | 0–8, Adult | 0–13, Adult | 0.4–0.5, Adult | 4–11 | 0–1, Adult | 0.5–5 | 0–1 | 0.1–1.5 | 0–1, Adult | 0.2–2, Adult |
| Sample type | PBMC | CBMC, PBMC | WB | CBMC, PBMC | WB | WB | WB | WB | WB | WB | WB | WB |
| Analysis method | ELISA | ELISA | CBA | TRF | xMAP | ELISA | xMAP | ELISA | xMAP | xMAP | xMAP | xMAP |
| Stimulant | SEB | LPS, KSA | PMA/iono | LPS | TLR2-agnoist LPS, PPD, PHA, LPS | PWM | LPS, TLR2-agonist, CpG | TLR-agonist 1–9, SEB | TLR-agonist 1–9, PMA/iono | TLR-agonist 2, 3, 4, 7/8, NOD 1, 2 ligand, Alum, LPS | NOD 1/2, TLR-agonist 1–4, 7, 8 | PHA |
| Incubation time (h) | 24 | 24 | 5, 10, 18, 24 | 2, 6, 24 | 24, 72 | 24, 120 | 16–18 | 24, 120 (SEB) | 18–24 | 24 | 18 | 24, 144 |
| INF-γ | – | – | PHA | LPS | SEB | TLR 1/2 | TLR2, 3 | All antigens | ||||
| PPD | TLR 3–9 | Alum, NOD 1, 2, TRL4, 7/8 | ||||||||||
| IL-4 | – | – | – | – | – | – | – | – | – | |||
| IL-5 | – | – | PHA | – | SEB | – | – | – | ||||
| PPD | – | |||||||||||
| IL-6 | – | – | – | – | – | LPS, CpG | TLR4, 6 | TLR9 | TLR2, 3 | NOD 1/2, TLR2/1, 7/8 | ||
| TLR1/2, 3, 5, 9 | TLR1–8 | Alum, NOD 1, 2, TLR4, 7/8 | TLR3, 4, 9 | |||||||||
| IL-8 | – | – | – | – | – | – | LPS | TLR1/2, 4, 5, 6, 9 | – | – | – | |
| TLR 3 | ||||||||||||
| IL-10 | – | LPS, PPD, PHA | LPS | SEB, TLR 1/2, 4, 5, 6 | TLR3, 9 | TLR3 | NOD 1/2, TLR2/1 | |||||
| TLR7, 8 | Alum, NOD 1, 2, TLR3, 4, 7/8 | TLR 2/1, 3, 4, 7/8, 9 | ||||||||||
| IL-12(p70) | – | – | – | – | LPS | – | – | TLR3 | – | – | ||
| IL-13 | – | – | – | – | – | SEB | – | – | – | |||
| TNF-α | – | – | LPS, TLR2 | – | LPS | TLR6, 9 | TLR 7/8, 9 | All antigens | NOD 1/2, TLR2/1 | |||
| PHA | TLR 1/2, 3, 4, 5 | TRL8 | ||||||||||
Negative age correlations are shown in red, positive age correlations in green, absence of age correlation (or not analyzed) in gray. Only parameters investigated in more than one study are listed.
CBA, cytometric bead array; KSA, heat-killed S. aureus; PWM, pokeweed mitogen; TLR, toll-like receptor; TRF, time resolved fluorometry; xMAP, multiplex bead-based immunoassay; CBMC, cord blood mononuclear cell; PBMC, peripheral blood mononuclear cell; PMA, phorbol-12-myristate-13-acetate; CPG, CpG-rich oligonucleotides.